Arielle G. Bensimon

Analysis Group (United States) — United States

Economics, Econometrics and Finance · Social Sciences

13h-index690citations55works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(14), Inflammatory Bowel Disease(10), Economic and Financial Impacts of Cancer(8), Microscopic Colitis(8), Cancer Immunotherapy and Biomarkers(6)

Publications55 total

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.
PubMed·2026
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States
Figshare·2026Open Access
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States
Figshare·2026Open Access
Patients with Atopic Dermatitis Reported Rapid and Optimal Real-World Effectiveness with Upadacitinib: SCALE-UP Study Results by Prior Treatment
SKIN The Journal of Cutaneous Medicine·2025Open Access
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.
JCO Oncology Practice·2025
Economic Value of Tocilizumab Prophylaxis to Prevent Cytokine Release Syndrome (CRS) during Outpatient Teclistamab (Tec) or Talquetamab (Tal) Initiation for Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada
Journal of Medical Economics·2025· 1 citedOpen Access
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States
Journal of Medical Economics·2025· 3 citedOpen Access
EE344 Updated Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Therapy for Renal Cell Carcinoma After Nephrectomy in the United States
Value in Health·2024Open Access
706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
British Journal of Dermatology·2024· 1 cited
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
Advances in Therapy·2023· 11 citedOpen Access
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
Clinical Genitourinary Cancer·2023· 13 cited
Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan.
Journal of Clinical Oncology·2023· 5 cited
EE371 Disease Management Costs for Patients With Intermediate-High or High-Risk Renal Cell Carcinoma (RCC) Following Nephrectomy
Value in Health·2022· 1 citedOpen Access
Indirect Cost Burden Attributable to Locally Advanced Head and Neck Squamous Cell Carcinoma in the United States
International Journal of Radiation Oncology*Biology*Physics·2022· 1 cited
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib
Value in Health·2022Open Access
POS0848 HEALTHCARE RESOURCE UTILIZATION AND COST BURDEN OF DERMATOMYOSITIS
Annals of the Rheumatic Diseases·2022· 1 citedOpen Access
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis
Journal of the American Academy of Dermatology·2021· 9 cited
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Advances in Therapy·2021· 7 citedOpen Access
Health care resource utilization and cost burden of hemophilia B in the United States
Blood Advances·2021· 32 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Eric Q. Wu(15), Parvez Mulani(10), Andrew P. Yu(9), Jingdong Chao(7), Yan Song(6), James Signorovitch(6), Ruifeng Xu(6), David T. Rubin(4), Zheng‐Yi Zhou(4), Joanne Chang(3), Kristijan H. Kahler(3), Thomas Fellers(3), John J. Orloff(3), Chun‐Po Steve Fan(3), Subrata Ghosh(3), Hongbo Yang(3), Clemens Krepler(3), Miranda Peeples(3), Vivian Herrera(3), Andrew Yu(3)